Cutera (NASDAQ:CUTR) Rating Reiterated by Stephens

Stephens reiterated their overweight rating on shares of Cutera (NASDAQ:CUTR) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $10.00 price target on the medical device company’s stock.

A number of other equities analysts have also recently weighed in on CUTR. Piper Sandler reaffirmed a neutral rating and issued a $3.00 price target on shares of Cutera in a report on Friday, June 21st. StockNews.com raised Cutera to a sell rating in a report on Friday, May 10th. Finally, William Blair raised Cutera from an underperform rating to a market perform rating in a report on Friday, March 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Hold and a consensus price target of $7.67.

Cutera Price Performance

Shares of NASDAQ:CUTR opened at $1.46 on Tuesday. The business’s 50-day moving average is $2.07 and its 200 day moving average is $2.38. Cutera has a 1 year low of $1.28 and a 1 year high of $21.41. The firm has a market capitalization of $29.35 million, a P/E ratio of -0.20 and a beta of 1.42.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Thursday, May 9th. The medical device company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.05). The business had revenue of $38.79 million during the quarter, compared to analyst estimates of $37.17 million. During the same quarter in the previous year, the firm posted ($1.26) EPS. On average, analysts expect that Cutera will post -5.88 EPS for the current year.

Insider Transactions at Cutera

In other news, EVP Michael Karavitis sold 24,940 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $2.59, for a total transaction of $64,594.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.42% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio purchased a new position in Cutera in the third quarter valued at $43,000. Tower Research Capital LLC TRC boosted its holdings in Cutera by 112.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,363 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 4,430 shares during the period. SG Americas Securities LLC purchased a new position in Cutera in the fourth quarter valued at $43,000. PNC Financial Services Group Inc. boosted its holdings in Cutera by 75.6% in the third quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the medical device company’s stock valued at $132,000 after purchasing an additional 9,472 shares during the period. Finally, Bayesian Capital Management LP purchased a new position in Cutera in the first quarter valued at $33,000. 90.70% of the stock is currently owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.